Self-Cleaning Mask with Antimicrobial Technology Deactivates 99% of Coronavirus Suspension in Minutes
By HospiMedica International staff writers Posted on 15 Jul 2020 |
Image: Self-Cleaning Mask with Antimicrobial Technology Deactivates 99% of Coronavirus Suspension in Minutes (Photo courtesy of i3 BioMedical Inc.)
Scientists have confirmed that a new surgical mask having an outer layer with interactive antimicrobial protection can deactivate >99% of the coronavirus suspension in minutes.
Scientists at the University of Toronto (Toronto, Canada) have tested and established that the SARS-CoV-2 virus cannot be recovered after being applied to i3 BioMedical Inc.’s (Quebec, Canada) TrioMed Active mask as its external surface deactivates >99% of the coronavirus suspension within minutes.
Previous studies have established that people touch their face 23 times per hour on average and that the coronavirus remains present and infectious on the outer layer of masks for up to seven days. In addition to the warnings issued by governmental authorities pertaining to self-contamination by touching one's mask, these studies further demonstrate the major deficiency in the level of protection for all wearers of current masks.
The TrioMed Active Mask type IIR surgical mask incorporates TrioMed's technology and provides an advanced level of active protection for healthcare workers and the general population. The patented antimicrobial technology is at the core of the company's entire line of medical products such as wound dressings, medical tapes, gloves, headwear, gowns and other personal protective equipment sold globally. The active antimicrobial protection of the mask’s outer layer deactivates >99% of the coronavirus SARS 2 and influenza virus H1N1. The TrioMed Active Mask type IIR surgical mask has viral filtration efficiency (VFE) of > 99.9% and bacterial filtration efficiency (BFE) of > 99.9%.
"The TrioMed Active Mask is the first and only respiratory protection that is scientifically proven to deactivate the virus causing COVID-19, therefore drastically reducing the risk of contamination for the wearer", said Pierre Jean Messier, founder and CEO of i3 Biomedical Inc. "Our company spent years and millions of dollars to develop this interactive antimicrobial technology. The resulting products are used by the medical community around the world and have been tested by independent laboratories to kill numerous microbes, such as MRSA, VRE, E-Coli, Staphylococcus Aureus, Influenza Virus and now SARS-CoV-2. This third-party scientific testing confirms TrioMed's leading position in medical antimicrobial technology available in the global fight against COVID-19."
Related Links:
i3 BioMedical Inc.
University of Toronto
Scientists at the University of Toronto (Toronto, Canada) have tested and established that the SARS-CoV-2 virus cannot be recovered after being applied to i3 BioMedical Inc.’s (Quebec, Canada) TrioMed Active mask as its external surface deactivates >99% of the coronavirus suspension within minutes.
Previous studies have established that people touch their face 23 times per hour on average and that the coronavirus remains present and infectious on the outer layer of masks for up to seven days. In addition to the warnings issued by governmental authorities pertaining to self-contamination by touching one's mask, these studies further demonstrate the major deficiency in the level of protection for all wearers of current masks.
The TrioMed Active Mask type IIR surgical mask incorporates TrioMed's technology and provides an advanced level of active protection for healthcare workers and the general population. The patented antimicrobial technology is at the core of the company's entire line of medical products such as wound dressings, medical tapes, gloves, headwear, gowns and other personal protective equipment sold globally. The active antimicrobial protection of the mask’s outer layer deactivates >99% of the coronavirus SARS 2 and influenza virus H1N1. The TrioMed Active Mask type IIR surgical mask has viral filtration efficiency (VFE) of > 99.9% and bacterial filtration efficiency (BFE) of > 99.9%.
"The TrioMed Active Mask is the first and only respiratory protection that is scientifically proven to deactivate the virus causing COVID-19, therefore drastically reducing the risk of contamination for the wearer", said Pierre Jean Messier, founder and CEO of i3 Biomedical Inc. "Our company spent years and millions of dollars to develop this interactive antimicrobial technology. The resulting products are used by the medical community around the world and have been tested by independent laboratories to kill numerous microbes, such as MRSA, VRE, E-Coli, Staphylococcus Aureus, Influenza Virus and now SARS-CoV-2. This third-party scientific testing confirms TrioMed's leading position in medical antimicrobial technology available in the global fight against COVID-19."
Related Links:
i3 BioMedical Inc.
University of Toronto
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans